,id,cid,dsn,cmpdname,srccmpd,srccmpdname,srccmpdurl,srctarget,srctargetname,srctargeturl,protacxn,protname,geneid,genename,taxid,taxname,action,actname,actvalue,evids,evurls,pmids,dois,citations
0,80439,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA1,https://www.dgidb.org/genes/KCNA1,,,3736.0,KCNA1,9606.0,Homo sapiens (human),,,,,,,,
1,80440,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNC4,https://www.dgidb.org/genes/KCNC4,,,3749.0,KCNC4,9606.0,Homo sapiens (human),Blocker,,,,,,,
2,80441,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNF1,https://www.dgidb.org/genes/KCNF1,,,3754.0,KCNF1,9606.0,Homo sapiens (human),Blocker,,,,,,,
3,80442,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA10,https://www.dgidb.org/genes/KCNA10,,,3744.0,KCNA10,9606.0,Homo sapiens (human),Blocker,,,,,,,
4,80443,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNB2,https://www.dgidb.org/genes/KCNB2,,,9312.0,KCNB2,9606.0,Homo sapiens (human),Blocker,,,,,,,
5,80444,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA1,https://www.dgidb.org/genes/KCNA1,,,3736.0,KCNA1,9606.0,Homo sapiens (human),Blocker,,,,,,,
6,80445,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9ULS6,Potassium voltage-gated channel subfamily S member 2,3788.0,KCNS2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
7,80446,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9ULD8,Potassium voltage-gated channel subfamily H member 3,23416.0,KCNH3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
8,80447,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9UQ05,Potassium voltage-gated channel subfamily H member 4,23415.0,KCNH4,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
9,80448,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,O43525,Potassium voltage-gated channel subfamily KQT member 3,3786.0,KCNQ3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
10,80449,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,O43526,Potassium voltage-gated channel subfamily KQT member 2,3785.0,KCNQ2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
11,80450,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,O95259,Potassium voltage-gated channel subfamily H member 1,3756.0,KCNH1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
12,80662,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P16389,Potassium voltage-gated channel subfamily A member 2,3737.0,KCNA2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
13,80663,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P17658,Potassium voltage-gated channel subfamily A member 6,3742.0,KCNA6,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
14,80664,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P48547,Potassium voltage-gated channel subfamily C member 1,3746.0,KCNC1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
15,80665,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
16,80666,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P22459,Potassium voltage-gated channel subfamily A member 4,3739.0,KCNA4,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
17,80667,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P22001,Potassium voltage-gated channel subfamily A member 3,3738.0,KCNA3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
18,80668,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q09470,Potassium voltage-gated channel subfamily A member 1,3736.0,KCNA1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
19,80669,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q12809,Potassium voltage-gated channel subfamily H member 2,3757.0,KCNH2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
20,80670,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P51787,Potassium voltage-gated channel subfamily KQT member 1,3784.0,KCNQ1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
21,80802,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,P56696,Potassium voltage-gated channel subfamily KQT member 4,9132.0,KCNQ4,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
22,80803,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q14721,Potassium voltage-gated channel subfamily B member 1,3745.0,KCNB1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
23,80804,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q03721,Potassium voltage-gated channel subfamily C member 4,3749.0,KCNC4,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
24,80805,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q14003,Potassium voltage-gated channel subfamily C member 3,3748.0,KCNC3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
25,80806,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q6PIU1,Potassium voltage-gated channel subfamily V member 1,27012.0,KCNV1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
26,80807,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q8NCM2,Potassium voltage-gated channel subfamily H member 5,27133.0,KCNH5,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
27,80808,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q8TDN1,Potassium voltage-gated channel subfamily G member 4,93107.0,KCNG4,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
28,80809,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
29,80810,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q8TDN2,Potassium voltage-gated channel subfamily V member 2,169522.0,KCNV2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
30,80961,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q8TAE7,Potassium voltage-gated channel subfamily G member 3,170850.0,KCNG3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
31,80962,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
32,80963,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q96KK3,Potassium voltage-gated channel subfamily S member 1,3787.0,KCNS1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
33,80964,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q96RP8,Potassium voltage-gated channel subfamily A member 7,3743.0,KCNA7,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
34,80965,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9H252,Potassium voltage-gated channel subfamily H member 6,81033.0,KCNH6,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
35,80966,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9H3M0,Potassium voltage-gated channel subfamily F member 1,3754.0,KCNF1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
36,80967,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9NR82,Potassium voltage-gated channel subfamily KQT member 5,56479.0,KCNQ5,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
37,80968,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9NS40,Potassium voltage-gated channel subfamily H member 7,90134.0,KCNH7,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
38,80969,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
39,81121,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9BQ31,Potassium voltage-gated channel subfamily S member 3,3790.0,KCNS3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
40,81122,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q96L42,Potassium voltage-gated channel subfamily H member 8,131096.0,KCNH8,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
41,81123,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q96PR1,Potassium voltage-gated channel subfamily C member 2,3747.0,KCNC2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
42,81124,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9UK17,Potassium voltage-gated channel subfamily D member 3,3752.0,KCND3,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
43,81125,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9UIX4,Potassium voltage-gated channel subfamily G member 1,3755.0,KCNG1,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
44,81126,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9UJ96,Potassium voltage-gated channel subfamily G member 2,26251.0,KCNG2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
45,81127,1727,ChEMBL,Dalfampridine,CHEMBL284348,DALFAMPRIDINE,https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL284348/,CHEMBL2362996,Voltage-gated potassium channel,https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL2362996/,Q9NZV8,Potassium voltage-gated channel subfamily D member 2,3751.0,KCND2,9606.0,Homo sapiens (human),Voltage-gated potassium channel blocker,,,PMID:21595605,https://www.ncbi.nlm.nih.gov/pubmed/21595605,21595605,,
46,83857,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNC3,https://www.dgidb.org/genes/KCNC3,,,3748.0,KCNC3,9606.0,Homo sapiens (human),Blocker,,,,,,,
47,83858,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNQ2,https://www.dgidb.org/genes/KCNQ2,,,3785.0,KCNQ2,9606.0,Homo sapiens (human),Blocker,,,,,,,
48,83859,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,552,Kv4.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=552,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),,pIC50,2,PMID:10729221,https://www.ncbi.nlm.nih.gov/pubmed/10729221,10729221,,
49,83860,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,552,Kv4.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=552,Q03719,Potassium voltage-gated channel subfamily D member 1,16506.0,Kcnd1,10090.0,Mus musculus (house mouse),,pIC50,2,PMID:11805342,https://www.ncbi.nlm.nih.gov/pubmed/11805342,11805342,,
50,84037,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,553,Kv4.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=553,Q9Z0V2,Potassium voltage-gated channel subfamily D member 2,16508.0,Kcnd2,10090.0,Mus musculus (house mouse),,pIC50,2.3,PMID:16317109,https://www.ncbi.nlm.nih.gov/pubmed/16317109,16317109,,
51,84038,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNB2,https://www.dgidb.org/genes/KCNB2,,,9312.0,KCNB2,9606.0,Homo sapiens (human),Blocker,,,,,,,
52,84039,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCND3,https://www.dgidb.org/genes/KCND3,,,3752.0,KCND3,9606.0,Homo sapiens (human),Blocker,,,,,,,
53,87932,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCND2,https://www.dgidb.org/genes/KCND2,,,3751.0,KCND2,9606.0,Homo sapiens (human),Blocker,,,,,,,
54,87933,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA7,https://www.dgidb.org/genes/KCNA7,,,3743.0,KCNA7,9606.0,Homo sapiens (human),Blocker,,,,,,,
55,95105,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA6,https://www.dgidb.org/genes/KCNA6,,,3742.0,KCNA6,9606.0,Homo sapiens (human),Blocker,,,,,,,
56,95106,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA5,https://www.dgidb.org/genes/KCNA5,,,3741.0,KCNA5,9606.0,Homo sapiens (human),Blocker,,,,,,,
57,95280,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNG3,https://www.dgidb.org/genes/KCNG3,,,170850.0,KCNG3,9606.0,Homo sapiens (human),Blocker,,,,,,,
58,106828,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,ERG,https://www.dgidb.org/genes/ERG,,,2078.0,ERG,9606.0,Homo sapiens (human),Blocker,,,,,,,
59,106829,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH8,https://www.dgidb.org/genes/KCNH8,,,131096.0,KCNH8,9606.0,Homo sapiens (human),Blocker,,,,,,,
60,107653,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,958,CD40,https://ctdbase.org/detail.go?type=gene&acc=958,,,958.0,CD40,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of CD40 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
61,107654,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003647,Solute carrier family 22 member 2,https://www.drugbank.ca/bio_entities/BE0003647,O15244,Solute carrier family 22 member 2,6582.0,SLC22A2,9606.0,Homo sapiens (human),Substrate,,,,,,,Fampyra (Fampridine) Canadian Prescribing Information|Fampyra - EMA Label|DALFAMPRIDINE Prescribing Information
62,107655,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0000781,Potassium voltage-gated channel subfamily A member 1,https://www.drugbank.ca/bio_entities/BE0000781,Q09470,Potassium voltage-gated channel subfamily A member 1,3736.0,KCNA1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
63,107656,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004715,Potassium voltage-gated channel subfamily A member 2,https://www.drugbank.ca/bio_entities/BE0004715,P16389,Potassium voltage-gated channel subfamily A member 2,3737.0,KCNA2,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
64,107657,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004716,Potassium voltage-gated channel subfamily A member 3,https://www.drugbank.ca/bio_entities/BE0004716,P22001,Potassium voltage-gated channel subfamily A member 3,3738.0,KCNA3,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
65,107658,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004502,Potassium voltage-gated channel subfamily A member 4,https://www.drugbank.ca/bio_entities/BE0004502,P22459,Potassium voltage-gated channel subfamily A member 4,3739.0,KCNA4,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
66,107659,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004717,Potassium voltage-gated channel subfamily A member 5,https://www.drugbank.ca/bio_entities/BE0004717,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
67,107660,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004718,Potassium voltage-gated channel subfamily A member 6,https://www.drugbank.ca/bio_entities/BE0004718,P17658,Potassium voltage-gated channel subfamily A member 6,3742.0,KCNA6,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
68,107796,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004719,Potassium voltage-gated channel subfamily A member 7,https://www.drugbank.ca/bio_entities/BE0004719,Q96RP8,Potassium voltage-gated channel subfamily A member 7,3743.0,KCNA7,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
69,107797,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004720,Potassium voltage-gated channel subfamily A member 10,https://www.drugbank.ca/bio_entities/BE0004720,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
70,107798,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004721,Potassium voltage-gated channel subfamily B member 1,https://www.drugbank.ca/bio_entities/BE0004721,Q14721,Potassium voltage-gated channel subfamily B member 1,3745.0,KCNB1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
71,107799,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004722,Potassium voltage-gated channel subfamily B member 2,https://www.drugbank.ca/bio_entities/BE0004722,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
72,107800,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004723,Potassium voltage-gated channel subfamily C member 1,https://www.drugbank.ca/bio_entities/BE0004723,P48547,Potassium voltage-gated channel subfamily C member 1,3746.0,KCNC1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
73,107801,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004724,Potassium voltage-gated channel subfamily C member 2,https://www.drugbank.ca/bio_entities/BE0004724,Q96PR1,Potassium voltage-gated channel subfamily C member 2,3747.0,KCNC2,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
74,107802,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004725,Potassium voltage-gated channel subfamily C member 3,https://www.drugbank.ca/bio_entities/BE0004725,Q14003,Potassium voltage-gated channel subfamily C member 3,3748.0,KCNC3,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
75,107803,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0004726,Potassium voltage-gated channel subfamily D member 1,https://www.drugbank.ca/bio_entities/BE0004726,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
76,107969,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003603,Potassium voltage-gated channel subfamily D member 2,https://www.drugbank.ca/bio_entities/BE0003603,Q9NZV8,Potassium voltage-gated channel subfamily D member 2,3751.0,KCND2,9606.0,Homo sapiens (human),Antagonist,,,PMID:23184313,https://www.ncbi.nlm.nih.gov/pubmed/23184313,23184313,,"Goodman AD, Stone RT: Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). Neurotherapeutics. 2013 Jan;10(1):106-10. doi: 10.1007/s13311-012-0156-3."
77,107970,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003604,Potassium voltage-gated channel subfamily D member 3,https://www.drugbank.ca/bio_entities/BE0003604,Q9UK17,Potassium voltage-gated channel subfamily D member 3,3752.0,KCND3,9606.0,Homo sapiens (human),Antagonist,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,"Judge SI, Bever CT Jr: Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9."
78,107971,1727,DrugBank,Dalfampridine,DB06637,Dalfampridine,https://www.drugbank.ca/drugs/DB06637,BE0003533,Cytochrome P450 2E1,https://www.drugbank.ca/bio_entities/BE0003533,P05181,Cytochrome P450 2E1,1571.0,CYP2E1,9606.0,Homo sapiens (human),Substrate,,,PMID:22764324,https://www.ncbi.nlm.nih.gov/pubmed/22764324,22764324,,"Pikoulas TE, Fuller MA: Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5. doi: 10.1345/aph.1Q714. Epub 2012  Jul 3."
79,107972,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCND1,https://www.dgidb.org/genes/KCND1,,,3750.0,KCND1,9606.0,Homo sapiens (human),Blocker,,,,,,,
80,107973,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNS1,https://www.dgidb.org/genes/KCNS1,,,3787.0,KCNS1,9606.0,Homo sapiens (human),Blocker,,,,,,,
81,107974,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA10,https://www.dgidb.org/genes/KCNA10,,,3744.0,KCNA10,9606.0,Homo sapiens (human),Blocker,,,,,,,
82,112715,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH4,https://www.dgidb.org/genes/KCNH4,,,23415.0,KCNH4,9606.0,Homo sapiens (human),Blocker,,,,,,,
83,112716,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH7,https://www.dgidb.org/genes/KCNH7,,,90134.0,KCNH7,9606.0,Homo sapiens (human),Blocker,,,,,,,
84,112717,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA5,https://www.dgidb.org/genes/KCNA5,,,3741.0,KCNA5,9606.0,Homo sapiens (human),Blocker,,,,,,,
85,112718,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNG2,https://www.dgidb.org/genes/KCNG2,,,26251.0,KCNG2,9606.0,Homo sapiens (human),Blocker,,,,,,,
86,115568,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNQ3,https://www.dgidb.org/genes/KCNQ3,,,3786.0,KCNQ3,9606.0,Homo sapiens (human),Blocker,,,,,,,
87,115569,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNQ4,https://www.dgidb.org/genes/KCNQ4,,,9132.0,KCNQ4,9606.0,Homo sapiens (human),Blocker,,,,,,,
88,115570,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNQ5,https://www.dgidb.org/genes/KCNQ5,,,56479.0,KCNQ5,9606.0,Homo sapiens (human),Blocker,,,,,,,
89,118852,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,959,CD40LG,https://ctdbase.org/detail.go?type=gene&acc=959,,,959.0,CD40LG,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of CD40LG mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
90,118853,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,1508,CTSB,https://ctdbase.org/detail.go?type=gene&acc=1508,,,1508.0,CTSB,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of CTSB mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
91,118854,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,10570,DPYSL4,https://ctdbase.org/detail.go?type=gene&acc=10570,,,10570.0,DPYSL4,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of DPYSL4 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
92,118855,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,7186,TRAF2,https://ctdbase.org/detail.go?type=gene&acc=7186,,,7186.0,TRAF2,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of TRAF2 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
93,118856,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,443,Kir7.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=443,O60928,Inward rectifier potassium channel 13,3769.0,KCNJ13,9606.0,Homo sapiens (human),Antagonist,,1.6,PMID:9620703,https://www.ncbi.nlm.nih.gov/pubmed/9620703,9620703,,
94,127116,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNC1,https://www.dgidb.org/genes/KCNC1,,,3746.0,KCNC1,9606.0,Homo sapiens (human),Blocker,,,,,,,
95,127117,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNV1,https://www.dgidb.org/genes/KCNV1,,,27012.0,KCNV1,9606.0,Homo sapiens (human),Blocker,,,,,,,
96,127118,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNG1,https://www.dgidb.org/genes/KCNG1,,,3755.0,KCNG1,9606.0,Homo sapiens (human),Blocker,,,,,,,
97,127716,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA2,https://www.dgidb.org/genes/KCNA2,,,3737.0,KCNA2,9606.0,Homo sapiens (human),Blocker,,,,,,,
98,127717,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,CALCA,https://www.dgidb.org/genes/CALCA,,,796.0,CALCA,9606.0,Homo sapiens (human),,,,,,,,
99,127718,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNS3,https://www.dgidb.org/genes/KCNS3,,,3790.0,KCNS3,9606.0,Homo sapiens (human),Blocker,,,,,,,
100,127719,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNS2,https://www.dgidb.org/genes/KCNS2,,,3788.0,KCNS2,9606.0,Homo sapiens (human),Blocker,,,,,,,
101,134752,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,550,Kv3.3,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=550,Q01956,Potassium voltage-gated channel subfamily C member 3,,,10116.0,Rattus norvegicus (Norway rat),,pIC50,2.9,PMID:1381835,https://www.ncbi.nlm.nih.gov/pubmed/1381835,1381835,,
102,134935,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,550,Kv3.3,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=550,,,117101.0,Kcnc3,10116.0,Rattus norvegicus (Norway rat),,pIC50,2.9,PMID:1381835,https://www.ncbi.nlm.nih.gov/pubmed/1381835,1381835,,
103,134936,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,554,Kv4.3,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=554,Q9Z0V1,Potassium voltage-gated channel subfamily D member 3,56543.0,Kcnd3,10090.0,Mus musculus (house mouse),,pIC50,2.4,PMID:17016508,https://www.ncbi.nlm.nih.gov/pubmed/17016508,17016508,,
104,134937,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,541,Kv1.4,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=541,P15385,Potassium voltage-gated channel subfamily A member 4,25469.0,Kcna4,10116.0,Rattus norvegicus (Norway rat),,pIC50,1.9,PMID:2555158,https://www.ncbi.nlm.nih.gov/pubmed/2555158,2555158,,
105,134938,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,544,Kv1.7,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=544,Q17ST2,Potassium voltage-gated channel subfamily A member 7,16495.0,Kcna7,10090.0,Mus musculus (house mouse),,pIC50,3.6,PMID:9488722,https://www.ncbi.nlm.nih.gov/pubmed/9488722,9488722,,
106,134939,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,544,Kv1.7,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=544,Q17ST2,Potassium voltage-gated channel subfamily A member 7,16495.0,Kcna7,10090.0,Mus musculus (house mouse),Pore blocker,pKd,3.8,PMID:16801386,https://www.ncbi.nlm.nih.gov/pubmed/16801386,16801386,,
107,139322,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH6,https://www.dgidb.org/genes/KCNH6,,,81033.0,KCNH6,9606.0,Homo sapiens (human),Blocker,,,,,,,
108,139323,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNV2,https://www.dgidb.org/genes/KCNV2,,,169522.0,KCNV2,9606.0,Homo sapiens (human),Blocker,,,,,,,
109,139324,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004721,Potassium voltage-gated channel subfamily B member 1,http://www.t3db.ca/biodb/bio_entities/BE0004721,Q14721,Potassium voltage-gated channel subfamily B member 1,3745.0,KCNB1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
110,139325,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004722,Potassium voltage-gated channel subfamily B member 2,http://www.t3db.ca/biodb/bio_entities/BE0004722,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
111,139326,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004723,Potassium voltage-gated channel subfamily C member 1,http://www.t3db.ca/biodb/bio_entities/BE0004723,P48547,Potassium voltage-gated channel subfamily C member 1,3746.0,KCNC1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
112,139327,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004724,Potassium voltage-gated channel subfamily C member 2,http://www.t3db.ca/biodb/bio_entities/BE0004724,Q96PR1,Potassium voltage-gated channel subfamily C member 2,3747.0,KCNC2,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
113,139328,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004725,Potassium voltage-gated channel subfamily C member 3,http://www.t3db.ca/biodb/bio_entities/BE0004725,Q14003,Potassium voltage-gated channel subfamily C member 3,3748.0,KCNC3,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
114,139329,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004726,Potassium voltage-gated channel subfamily D member 1,http://www.t3db.ca/biodb/bio_entities/BE0004726,Q9NSA2,Potassium voltage-gated channel subfamily D member 1,3750.0,KCND1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
115,139330,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0003603,Potassium voltage-gated channel subfamily D member 2,http://www.t3db.ca/biodb/bio_entities/BE0003603,Q9NZV8,Potassium voltage-gated channel subfamily D member 2,3751.0,KCND2,9606.0,Homo sapiens (human),,,,PMID:23184313,https://www.ncbi.nlm.nih.gov/pubmed/23184313,23184313,,
116,139331,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0003604,Potassium voltage-gated channel subfamily D member 3,http://www.t3db.ca/biodb/bio_entities/BE0003604,Q9UK17,Potassium voltage-gated channel subfamily D member 3,3752.0,KCND3,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
117,139332,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0000090,Potassium voltage-gated channel subfamily H member 2,http://www.t3db.ca/biodb/bio_entities/BE0000090,Q12809,Potassium voltage-gated channel subfamily H member 2,3757.0,KCNH2,9606.0,Homo sapiens (human),,,,PMID:15324906,https://www.ncbi.nlm.nih.gov/pubmed/15324906,15324906,,
118,139490,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004717,Potassium voltage-gated channel subfamily A member 5,http://www.t3db.ca/biodb/bio_entities/BE0004717,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
119,139491,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004718,Potassium voltage-gated channel subfamily A member 6,http://www.t3db.ca/biodb/bio_entities/BE0004718,P17658,Potassium voltage-gated channel subfamily A member 6,3742.0,KCNA6,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
120,139492,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004719,Potassium voltage-gated channel subfamily A member 7,http://www.t3db.ca/biodb/bio_entities/BE0004719,Q96RP8,Potassium voltage-gated channel subfamily A member 7,3743.0,KCNA7,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
121,219030,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH3,https://www.dgidb.org/genes/KCNH3,,,23416.0,KCNH3,9606.0,Homo sapiens (human),Blocker,,,,,,,
122,219031,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,SLC22A2,https://www.dgidb.org/genes/SLC22A2,,,6582.0,SLC22A2,9606.0,Homo sapiens (human),,,,PMID:24433361,https://www.ncbi.nlm.nih.gov/pubmed/24433361,24433361,,
123,243508,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA1,https://www.dgidb.org/genes/KCNA1,,,3736.0,KCNA1,9606.0,Homo sapiens (human),,,,,,,,
124,243509,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNJ13,https://www.dgidb.org/genes/KCNJ13,,,3769.0,KCNJ13,9606.0,Homo sapiens (human),Blocker,,,,,,,
125,343692,1727,BindingDB,Dalfampridine,10458,4-AP,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10458,1043,Acetylcholinesterase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1043,P37136,Acetylcholinesterase,83817.0,Ache,10116.0,Rattus norvegicus (Norway rat),,IC50 (nM),>500000,PMID:10632067,https://www.ncbi.nlm.nih.gov/pubmed/10632067,10632067,,
126,343693,1727,BindingDB,Dalfampridine,10458,4-AP,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10458,1044,Carboxylic ester hydrolase,https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=1044,,,,,,,,IC50 (nM),>500000,PMID:10632067,https://www.ncbi.nlm.nih.gov/pubmed/10632067,10632067,,
127,343694,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCND1,https://www.dgidb.org/genes/KCND1,,,3750.0,KCND1,9606.0,Homo sapiens (human),Blocker,,,,,,,
128,343695,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNQ1,https://www.dgidb.org/genes/KCNQ1,,,3784.0,KCNQ1,9606.0,Homo sapiens (human),Blocker,,,,,,,
129,343696,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNB1,https://www.dgidb.org/genes/KCNB1,,,3745.0,KCNB1,9606.0,Homo sapiens (human),Blocker,,,,,,,
130,343697,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNC2,https://www.dgidb.org/genes/KCNC2,,,3747.0,KCNC2,9606.0,Homo sapiens (human),Blocker,,,,,,,
131,343698,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA4,https://www.dgidb.org/genes/KCNA4,,,3739.0,KCNA4,9606.0,Homo sapiens (human),Blocker,,,,,,,
132,343699,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH5,https://www.dgidb.org/genes/KCNH5,,,27133.0,KCNH5,9606.0,Homo sapiens (human),Blocker,,,,,,,
133,434110,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNA3,https://www.dgidb.org/genes/KCNA3,,,3738.0,KCNA3,9606.0,Homo sapiens (human),Blocker,,,,,,,
134,434111,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,508,TRPV2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=508,Q9WTR1,Transient receptor potential cation channel subfamily V member 2,22368.0,Trpv2,10090.0,Mus musculus (house mouse),Inhibition,,6.2,PMID:17673572,https://www.ncbi.nlm.nih.gov/pubmed/17673572,17673572,,
135,434550,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,539,Kv1.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=539,P63142,Potassium voltage-gated channel subfamily A member 2,25468.0,Kcna2,10116.0,Rattus norvegicus (Norway rat),Pore blocker,pKd,3.2,PMID:7517498,https://www.ncbi.nlm.nih.gov/pubmed/7517498,7517498,,
136,434551,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,542,Kv1.5,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542,P22460,Potassium voltage-gated channel subfamily A member 5,3741.0,KCNA5,9606.0,Homo sapiens (human),Pore blocker,pKd,3.6,PMID:7517498,https://www.ncbi.nlm.nih.gov/pubmed/7517498,7517498,,
137,434552,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,545,Kv1.8,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=545,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),,pIC50,2.8,PMID:10836990,https://www.ncbi.nlm.nih.gov/pubmed/10836990,10836990,,
138,434553,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,546,Kv2.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=546,P15387,Potassium voltage-gated channel subfamily B member 1,25736.0,Kcnb1,10116.0,Rattus norvegicus (Norway rat),Pore blocker,pIC50,3.3,PMID:8301258,https://www.ncbi.nlm.nih.gov/pubmed/8301258,8301258,,
139,434554,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,547,Kv2.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=547,Q92953,Potassium voltage-gated channel subfamily B member 2,9312.0,KCNB2,9606.0,Homo sapiens (human),,pIC50,2.8,PMID:9612272,https://www.ncbi.nlm.nih.gov/pubmed/9612272,9612272,,
140,434555,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,548,Kv3.1,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=548,P15388,Potassium voltage-gated channel subfamily C member 1,16502.0,Kcnc1,10090.0,Mus musculus (house mouse),,pIC50,4.5,PMID:7517498,https://www.ncbi.nlm.nih.gov/pubmed/7517498,7517498,,
141,434556,1727,IUPHAR/BPS Guide to PHARMACOLOGY,Dalfampridine,2416,fampridine,https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2416,549,Kv3.2,https://guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=549,P22462,Potassium voltage-gated channel subfamily C member 2,246153.0,Kcnc2,10116.0,Rattus norvegicus (Norway rat),,pIC50,4.6,PMID:11790809,https://www.ncbi.nlm.nih.gov/pubmed/11790809,11790809,,
142,666215,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004716,Potassium voltage-gated channel subfamily A member 3,http://www.t3db.ca/biodb/bio_entities/BE0004716,P22001,Potassium voltage-gated channel subfamily A member 3,3738.0,KCNA3,9606.0,Homo sapiens (human),,,,PMID:16472864|PMID:15084131,https://www.ncbi.nlm.nih.gov/pubmed/16472864|https://www.ncbi.nlm.nih.gov/pubmed/15084131,16472864|15084131,,
143,666216,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0000781,Potassium voltage-gated channel subfamily A member 1,http://www.t3db.ca/biodb/bio_entities/BE0000781,Q09470,Potassium voltage-gated channel subfamily A member 1,3736.0,KCNA1,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
144,666217,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004720,Potassium voltage-gated channel subfamily A member 10,http://www.t3db.ca/biodb/bio_entities/BE0004720,Q16322,Potassium voltage-gated channel subfamily A member 10,3744.0,KCNA10,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
145,666218,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004715,Potassium voltage-gated channel subfamily A member 2,http://www.t3db.ca/biodb/bio_entities/BE0004715,P16389,Potassium voltage-gated channel subfamily A member 2,3737.0,KCNA2,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
146,666219,1727,Toxin and Toxin Target Database (T3DB),Dalfampridine,T3D2553,4-Aminopyridine ,http://www.t3db.ca/toxins/T3D2553,BE0004502,Potassium voltage-gated channel subfamily A member 4,http://www.t3db.ca/biodb/bio_entities/BE0004502,P22459,Potassium voltage-gated channel subfamily A member 4,3739.0,KCNA4,9606.0,Homo sapiens (human),,,,PMID:16472864,https://www.ncbi.nlm.nih.gov/pubmed/16472864,16472864,,
147,666220,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,KCNH1,https://www.dgidb.org/genes/KCNH1,,,3756.0,KCNH1,9606.0,Homo sapiens (human),Blocker,,,,,,,
148,666221,1727,Drug Gene Interaction database (DGIdb),Dalfampridine,,DALFAMPRIDINE,https://www.dgidb.org/drugs/DALFAMPRIDINE,,CYP2D6,https://www.dgidb.org/genes/CYP2D6,,,1565.0,CYP2D6,9606.0,Homo sapiens (human),,,,,,,,
149,666222,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,147,ADRA1B,https://ctdbase.org/detail.go?type=gene&acc=147,,,147.0,ADRA1B,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to phenylephrine],,,PMID:18480251,https://www.ncbi.nlm.nih.gov/pubmed/18480251,18480251,,
150,666223,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,581,BAX,https://ctdbase.org/detail.go?type=gene&acc=581,,,581.0,BAX,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of BAX mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
151,666417,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,329,BIRC2,https://ctdbase.org/detail.go?type=gene&acc=329,,,329.0,BIRC2,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of BIRC2 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
152,666418,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,330,BIRC3,https://ctdbase.org/detail.go?type=gene&acc=330,,,330.0,BIRC3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of BIRC3 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
153,666419,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,90427,BMF,https://ctdbase.org/detail.go?type=gene&acc=90427,,,90427.0,BMF,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of BMF mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
154,666420,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,54991,C1ORF159,https://ctdbase.org/detail.go?type=gene&acc=54991,,,54991.0,C1orf159,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of C1ORF159 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
155,666421,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,836,CASP3,https://ctdbase.org/detail.go?type=gene&acc=836,,,836.0,CASP3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased activity of CASP3 protein,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
156,666422,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,840,CASP7,https://ctdbase.org/detail.go?type=gene&acc=840,,,840.0,CASP7,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased activity of CASP7 protein,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
157,666423,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,842,CASP9,https://ctdbase.org/detail.go?type=gene&acc=842,,,842.0,CASP9,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased activity of CASP9 protein,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
158,666424,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,2572,GAD2,https://ctdbase.org/detail.go?type=gene&acc=2572,,,2572.0,GAD2,10116.0,Rattus norvegicus (Norway rat),KCNIP1 mRNA promotes the reaction [4-aminopyridine results in increased expression of GAD2 mrna]|4-aminopyridine results in increased expression of GAD2 mRNA,,,PMID:25917026,https://www.ncbi.nlm.nih.gov/pubmed/25917026,25917026,,
159,666425,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,11227,GALNT5,https://ctdbase.org/detail.go?type=gene&acc=11227,,,11227.0,GALNT5,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of GALNT5 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
160,666426,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,2906,GRIN2D,https://ctdbase.org/detail.go?type=gene&acc=2906,,,2906.0,GRIN2D,10090.0,Mus musculus (house mouse),[bicuculline co-treated with 4-aminopyridine] results in decreased expression of GRIN2D protein,,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
161,666732,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,10014,HDAC5,https://ctdbase.org/detail.go?type=gene&acc=10014,,,10014.0,HDAC5,10116.0,Rattus norvegicus (Norway rat),[bicuculline co-treated with 4-aminopyridine] affects the localization of HDAC5 protein,,,PMID:15773917,https://www.ncbi.nlm.nih.gov/pubmed/15773917,15773917,,
162,666733,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,57338,JPH3,https://ctdbase.org/detail.go?type=gene&acc=57338,,,57338.0,JPH3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of JPH3 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
163,666734,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3744,KCNA10,https://ctdbase.org/detail.go?type=gene&acc=3744,,,3744.0,KCNA10,9606.0,Homo sapiens (human),4-aminopyridine inhibits the reaction [KCNA10 protein results in increased transport of potassium],,,PMID:10836990,https://www.ncbi.nlm.nih.gov/pubmed/10836990,10836990,,
164,666735,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3741,KCNA5,https://ctdbase.org/detail.go?type=gene&acc=3741,,,3741.0,KCNA5,9606.0,Homo sapiens (human),4-aminopyridine results in decreased activity of KCNA5 protein,,,PMID:23261645,https://www.ncbi.nlm.nih.gov/pubmed/23261645,23261645,,
165,666736,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3752,KCND3,https://ctdbase.org/detail.go?type=gene&acc=3752,,,3752.0,KCND3,10116.0,Rattus norvegicus (Norway rat),KCNIP1 mRNA promotes the reaction [4-aminopyridine results in increased expression of KCND3 mrna]|4-aminopyridine results in increased expression of KCND3 mRNA,,,PMID:25917026,https://www.ncbi.nlm.nih.gov/pubmed/25917026,25917026,,
166,666737,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,3757,KCNH2,https://ctdbase.org/detail.go?type=gene&acc=3757,,,3757.0,KCNH2,9606.0,Homo sapiens (human),4-aminopyridine results in decreased activity of KCNH2 protein,,,PMID:19915712,https://www.ncbi.nlm.nih.gov/pubmed/19915712,19915712,,
167,666738,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,30820,KCNIP1,https://ctdbase.org/detail.go?type=gene&acc=30820,,,30820.0,KCNIP1,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of KCNIP1 mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
168,666739,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,30820,KCNIP1,https://ctdbase.org/detail.go?type=gene&acc=30820,,,30820.0,KCNIP1,10116.0,Rattus norvegicus (Norway rat),KCNIP1 mRNA promotes the reaction [4-aminopyridine results in increased expression of KCND3 mrna]|4-aminopyridine results in increased expression of KCNIP1 mrna|kcnip1 mRNA promotes the reaction [4-aminopyridine results in increased abundance of gamma-aminobutyric acid]|kcnip1 mRNA promotes the reaction [4-aminopyridine results in increased expression of GAD2 mrna],,,PMID:25917026,https://www.ncbi.nlm.nih.gov/pubmed/25917026,25917026,,
169,666740,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,4099,MAG,https://ctdbase.org/detail.go?type=gene&acc=4099,,,4099.0,MAG,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of MAG mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
170,666741,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,84557,MAP1LC3A,https://ctdbase.org/detail.go?type=gene&acc=84557,,,84557.0,MAP1LC3A,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased expression of MAP1LC3A mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
171,667282,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10090.0,Mus musculus (house mouse),[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein|dizocilpine maleate inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein],,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
172,667283,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),Hispidulin inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK1 protein]|2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK1 protein],,,PMID:22759588,https://www.ncbi.nlm.nih.gov/pubmed/22759588,22759588,,
173,667284,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK1 protein|typhaneoside inhibits the reaction [[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK1 protein],,,PMID:33621091,https://www.ncbi.nlm.nih.gov/pubmed/33621091,33621091,,
174,667285,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased phosphorylation of MAPK1 protein,,,PMID:22759588|PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/22759588|https://www.ncbi.nlm.nih.gov/pubmed/28132918,22759588|28132918,,
175,667286,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5594,MAPK1,https://ctdbase.org/detail.go?type=gene&acc=5594,,,5594.0,MAPK1,10116.0,Rattus norvegicus (Norway rat),Ciproxifan inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK1 protein],,,PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/28132918,28132918,,
176,667287,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10090.0,Mus musculus (house mouse),Dizocilpine maleate inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein]|[bicuculline co-treated with 4-aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein,,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
177,667288,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),Hispidulin inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK3 protein]|2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK3 protein],,,PMID:22759588,https://www.ncbi.nlm.nih.gov/pubmed/22759588,22759588,,
178,667289,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),Typhaneoside inhibits the reaction [[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK3 protein]|[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of MAPK3 protein,,,PMID:33621091,https://www.ncbi.nlm.nih.gov/pubmed/33621091,33621091,,
179,667290,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased phosphorylation of MAPK3 protein,,,PMID:22759588|PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/22759588|https://www.ncbi.nlm.nih.gov/pubmed/28132918,22759588|28132918,,
180,668119,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5595,MAPK3,https://ctdbase.org/detail.go?type=gene&acc=5595,,,5595.0,MAPK3,10116.0,Rattus norvegicus (Norway rat),Ciproxifan inhibits the reaction [4-aminopyridine results in increased phosphorylation of MAPK3 protein],,,PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/28132918,28132918,,
181,668120,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,9612,NCOR2,https://ctdbase.org/detail.go?type=gene&acc=9612,,,9612.0,NCOR2,10116.0,Rattus norvegicus (Norway rat),KN 62 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein]|2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein]|sto 609 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein]|[bicuculline co-treated with 4-aminopyridine] affects the localization of NCOR2 protein,,,PMID:15773917,https://www.ncbi.nlm.nih.gov/pubmed/15773917,15773917,,
182,668121,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,258881,OR10J3B,https://ctdbase.org/detail.go?type=gene&acc=258881,,,258881.0,Or10j3b,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of OR10J3B mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
183,668122,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5327,PLAT,https://ctdbase.org/detail.go?type=gene&acc=5327,,,5327.0,PLAT,9606.0,Homo sapiens (human),[bicuculline co-treated with 4-aminopyridine co-treated with dizocilpine maleate] results in decreased susceptibility to PLAT protein,,,PMID:19911010,https://www.ncbi.nlm.nih.gov/pubmed/19911010,19911010,,
184,668123,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5566,PRKACA,https://ctdbase.org/detail.go?type=gene&acc=5566,,,5566.0,PRKACA,10116.0,Rattus norvegicus (Norway rat),Lappaconitine inhibits the reaction [4-aminopyridine results in increased phosphorylation of PRKACA protein]|4-aminopyridine results in increased phosphorylation of PRKACA protein,,,PMID:35643327,https://www.ncbi.nlm.nih.gov/pubmed/35643327,35643327,,
185,668124,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,5914,RARA,https://ctdbase.org/detail.go?type=gene&acc=5914,,,5914.0,RARA,10116.0,Rattus norvegicus (Norway rat),[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]|dizocilpine maleate inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]|kn 62 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]|sto 609 inhibits the reaction [[bicuculline co-treated with 4-aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]],,,PMID:15773917,https://www.ncbi.nlm.nih.gov/pubmed/15773917,15773917,,
186,668125,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,338324,S100A7A,https://ctdbase.org/detail.go?type=gene&acc=338324,,,338324.0,S100A7A,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in decreased expression of S100A7A mRNA,,,PMID:24378259,https://www.ncbi.nlm.nih.gov/pubmed/24378259,24378259,,
187,668126,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6616,SNAP25,https://ctdbase.org/detail.go?type=gene&acc=6616,,,6616.0,SNAP25,10116.0,Rattus norvegicus (Norway rat),4-aminopyridine results in increased phosphorylation of SNAP25 protein|lappaconitine inhibits the reaction [4-aminopyridine results in increased phosphorylation of SNAP25 protein],,,PMID:35643327,https://www.ncbi.nlm.nih.gov/pubmed/35643327,35643327,,
188,668127,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6853,SYN1,https://ctdbase.org/detail.go?type=gene&acc=6853,,,6853.0,SYN1,10090.0,Mus musculus (house mouse),SYN1 protein affects the susceptibility to 4-aminopyridine,,,PMID:22759588,https://www.ncbi.nlm.nih.gov/pubmed/22759588,22759588,,
189,668320,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6853,SYN1,https://ctdbase.org/detail.go?type=gene&acc=6853,,,6853.0,SYN1,10090.0,Mus musculus (house mouse),4-aminopyridine results in increased expression of SYN1 protein modified form|ciproxifan inhibits the reaction [4-aminopyridine results in increased expression of SYN1 protein modified form]|syn1 results in increased susceptibility to 4-aminopyridine,,,PMID:28132918,https://www.ncbi.nlm.nih.gov/pubmed/28132918,28132918,,
190,668321,1727,Comparative Toxicogenomics Database (CTD),Dalfampridine,D015761,4-Aminopyridine,https://ctdbase.org/detail.go?type=chem&acc=D015761,6853,SYN1,https://ctdbase.org/detail.go?type=gene&acc=6853,,,6853.0,SYN1,10116.0,Rattus norvegicus (Norway rat),Typhaneoside inhibits the reaction [[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of SYN1 protein]|[4-aminopyridine co-treated with calcium chloride] results in increased phosphorylation of SYN1 protein,,,PMID:33621091,https://www.ncbi.nlm.nih.gov/pubmed/33621091,33621091,,
191,668322,1727,BindingDB,Dalfampridine,10458,4-AP,https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10458,8498,Twik-RElated Potassium (K+) channel 1 (TREK1),https://www.bindingdb.org/rwd/jsp/dbsearch/PrimarySearch_ki.jsp?tag=pol&polymerid=8498,O95069,Potassium channel subfamily K member 2,3776.0,KCNK2,9606.0,Homo sapiens (human),,,,PMID:27346364,https://www.ncbi.nlm.nih.gov/pubmed/27346364,27346364,,
